News Formal

Johnson & Johnson beats on earnings, hikes full-year guidance as medtech sales surge

  • 📰 CNBC
  • ⏱ Reading Time:
  • 22 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 12%
  • Publisher: 72%

Belgique Nouvelles Nouvelles

Belgique Dernières Nouvelles,Belgique Actualités

The results come amid investor anxiety over the thousands of lawsuits claiming that J&J's talc-based baby powder and other products caused cancer.

Here's how J&J results compared with Wall Street expectations, based on a survey of analysts by Refinitiv:$25.53 billion, vs. $24.62 billion expected

The pharmaceutical giant reported a net income of $5.14 billion, or $1.96 per share. That compares with a net income of $4.8 billion, or $1.80 per share, for theShares of J&J have dropped more than 10% for the year, putting the company's market value at roughly $412 billion. The company raised its 2023 adjusted earnings outlook to $10.70 to $10.80 per share, from a previous forecast of $10.60 to $10.70 per share.

 

Merci pour votre commentaire. Votre commentaire sera publié après examen.
Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite:

 /  🏆 12. in BE

Belgique Dernières Nouvelles, Belgique Actualités

Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.

Johnson & Johnson must pay $18.8 million to California cancer patient in baby powder suit | CNN BusinessJohnson & Johnson must pay $18.8 million to a California man who said he developed cancer from exposure to its baby powder, a jury decided on Tuesday, a setback for the company as it seeks to settle thousands of similar cases over its talc-based products in US bankruptcy court.
La source: CNN - 🏆 4. / 95 Lire la suite »